Profiles

Gheorghe Doros, PhD

Professor, Biostatistics - Boston University School of Public Health

617-358-2494
doros@bu.edu
Crosstown Center - 331
View Full Profile at BUMC

Biography

Gheorghe Doros is Professor of Biostatistics and director of the Biostatistics Consulting Group. He received his PhD in Statistics from Yale University and joined BUSPH’s Department of Biostatistics in 2006 after spending two years at Eli Lilly, as a member of that company's Drug Discovery and Toxicology department. Dr. Doros’s research on methodological approaches and strategies has been concentrated in the area of clinical trials, more specifically on Bayesian approaches to clinical trials and the area of placebo response in clinical trials. The outcome of his work has been a corner stone in developing a host of collaborations with outstanding faculty, clinicians, and researchers at the Boston University Medical Campus and at other institutions. These productive collaborations have resulted in several federally funded grants. Dr. Doros authored and co-authored many peer-reviewed publications of original and innovative research which has had a major impact on the field. On the majority of publications, Dr. Doros is the lead statistician author. He demonstrated continuing record of multidisciplinary research that has had a major impact on the rapidly changing field. His publications on clinical trials; most proposing the design, analysis and new methodologies or of significant contributions to this field.

Dr. Doros is a very active and effective teacher and mentor in the department of Biostatistics. His teaching philosophy is to pursue an active approach to learning and to engage students to think critically. He taught core and elective courses for Master and PhD-level courses. The excellent course evaluations he received attests to his ability in engaging students in active learning. Dr. Doros has been awarded the excellence in teaching three times in three years.

On a national level, Dr. Doros has served as an Associate Editor for the BioMed Central’s journal Trials and as a reviewer for a number of academic journals. He served as a member of the merit review subcommittee for Epidemiology of the Department of Veteran Affairs and a member NHLBI-Ancillary Studies in Clinical Trials between 2012 and 2014. He has served as a statistical expert on a number of Independent Data Monitoring Committee(IDMC) for clinical trials and clinical programs. He served or seves as a senior consultant on multicenter trials and/or programs for the following organizations Pfizer, Takeda, Avanir, Sarepta and Children's Hospital.

Other Positions

  • Member, BU-BMC Cancer Center - Boston University
  • - Boston Medical Center

Education

  • Yale University, PhD Field of Study: Statistics
  • Yale University, MA Field of Study: Statistics
  • University of Bucharest, MS Field of Study: Statistics
  • University of Bucharest, BS Field of Study: Mathematics

Websites

Classes Taught

  • SPHBS849
  • SPHBS853
  • SPHBS854
  • SPHBS980

Publications

  • Published on 2/25/2025

    Powell RJ, Farber A, Doros G, Chew D, Conte MS, Dake MD, Kiang S, Menard MT, Rosenfeld K, Schneider PA, Siracuse JJ, Shaw P, Strong MB, Todoran T, White CJ, Kaufman JA. The Incidence and Consequences of Endovascular Technical Failure in Patients with Chronic Limb Threatening Ischemia: Results from the BEST-CLI Trial. J Vasc Interv Radiol. 2025 Feb 25. PMID: 40015448.

     Read At: PubMed
  • Published on 2/19/2025

    Barleben AR, Patel RJ, Farber A, Menard MT, Venermo M, Creager MA, Reitz KM, Strong M, Rosenfield K, Doros G, Dake M, Chaer RA. An assessment of the BEST-CLI Trial demonstrates that infrainguinal bypass offers a potential advantage in smokers with chronic limb-threatening ischemia. J Vasc Surg. 2025 Feb 19. PMID: 39984143.

     Read At: PubMed
  • Published on 2/12/2025

    Cutlip DE, Mehran R, Doros G, Kaplinskiy V, Lee J, Zheng L, Kausik M, Osborn E, Waksman R. Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design. Am Heart J. 2025 Jun; 284:11-19. PMID: 39952378.

     Read At: PubMed
  • Published on 2/4/2025

    Ulloa JG, Alabi O, McGinigle K, Lane J, Doros G, Menard M, Moreira CC, Judelson DR, Farber A, Conte MS, Rosenfeld K, Hamouda M, Kirksey L, Strong MB, Malas M, Kernodle A, Rowe VL. Outcomes for Hispanic patients undergoing open bypass in BEST-CLI. J Vasc Surg. 2025 Feb 04. PMID: 39914761.

     Read At: PubMed
  • Published on 1/23/2025

    Malas MB, Hamouda M, Farber A, Menard MT, Conte MS, Rosenfield K, Strong MB, Doros G, Powell RJ, Mena-Hurtado C, Gasper W, Schermerhorn ML, Allievi S, Smolderen KG, Dake MD, Rymer JA, Tuttle KR. Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial. J Vasc Surg. 2025 Apr; 81(4):945-956.e3. PMID: 39846933.

     Read At: PubMed
  • Published on 12/3/2024

    Siracuse JJ, Farber A, Menard MT, Rosenfield K, Conte MS, Schanzer A, Doros G, Motaganahalli R, Laskowski IJ, Barshes NR, Genovese EA, Strong MB, Mills JL. Advanced Wound, Ischemia, and Foot Infection stage is associated with poor outcomes in the BEST-CLI trial. J Vasc Surg. 2025 Mar; 81(3):720-729.e1. PMID: 39638100.

     Read At: PubMed
  • Published on 10/4/2024

    McGinigle KL, Doros G, Alabi O, Brooke BS, Vouyouka A, Hiramoto J, Charlton-Ouw K, Strong MB, Rosenfield K, Menard MT, Farber A, Giles KA. Female patients have fewer limb amputations compared to male patients in the BEST-CLI trial. J Vasc Surg. 2025 Feb; 81(2):366-373.e1. PMID: 39368637.

     Read At: PubMed
  • Published on 9/25/2024

    Ochoa Chaar CI, Malas M, Doros G, Schermerhorn M, Conte MS, Alameddine D, Siracuse JJ, Yadavalli SD, Dake MD, Creager MA, Tan TW, Rosenfield K, Menard MT, Farber A, Hamdan A. The impact of diabetes mellitus on the outcomes of revascularization for chronic limb-threatening ischemia in the BEST-CLI trial. J Vasc Surg. 2025 Feb; 81(2):376-385.e3. PMID: 39332785.

     Read At: PubMed
  • Published on 9/23/2024

    Farber A, Menard MT, Conte MS, Rosenfield K, Schermerhorn M, Schanzer A, Powell RJ, Chaar CIO, Hicks CW, Doros G, Strong MB, Leers SA, Motaganahalli R, Stangenberg L, Siracuse JJ. Prosthetic conduits have worse outcomes compared with great saphenous vein conduits in femoropopliteal and infrapopliteal bypass in patients with chronic limb-threatening ischemia. J Vasc Surg. 2025 Feb; 81(2):408-416.e2. PMID: 39321895.

     Read At: PubMed
  • Published on 9/12/2024

    Caliskan E, Misfeld M, Sandner S, Böning A, Aramendi J, Salzberg SP, Choi YH, Perrault LP, Tekin I, Cuerpo GP, Lopez-Menendez J, Weltert LP, Böhm J, Krane M, González-Santos JM, Tellez JC, Holubec T, Ferrari E, Doros G, Emmert MY. Transatlantic analysis of patient profiles and mid-term survival after isolated coronary artery bypass grafting: a head-to-head comparison between the European DuraGraft Registry and the US STS Registry. Front Cardiovasc Med. 2024; 11:1366460. PMID: 39346099.

     Read At: PubMed

View 350 more publications:View Full Profile at BUMC

News & In the Media

View all profiles